780 related articles for article (PubMed ID: 19666647)
1. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
2. New insights into the antibacterial mechanism of action of squalamine.
Alhanout K; Malesinki S; Vidal N; Peyrot V; Rolain JM; Brunel JM
J Antimicrob Chemother; 2010 Aug; 65(8):1688-93. PubMed ID: 20551217
[TBL] [Abstract][Full Text] [Related]
3. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species.
Farrell DJ; Robbins M; Rhys-Williams W; Love WG
Int J Antimicrob Agents; 2010 Jun; 35(6):531-6. PubMed ID: 20346634
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
Hadjivassileva T; Thurston DE; Taylor PW
J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial agents and cystic fibrosis: synthesis and antimicrobial evaluation of a series of N-thiomethylazetidinones.
Galletti P; Cocuzza CE; Pori M; Quintavalla A; Musumeci R; Giacomini D
ChemMedChem; 2011 Oct; 6(10):1919-27. PubMed ID: 21834093
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
Somily AM; Al-Khattaf AS; Kambal AM
Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
[TBL] [Abstract][Full Text] [Related]
10. Microbiological characterization of dactimicin: antibacterial activity towards gram-positive and gram-negative bacteria.
Stefani S; Debbia EA; Schito GC; Russo G
Drugs Exp Clin Res; 1989; 15(3):119-23. PubMed ID: 2752910
[TBL] [Abstract][Full Text] [Related]
11. Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis.
Alhanout K; Brunel JM; Dubus JC; Rolain JM; Andrieu V
J Antimicrob Chemother; 2011 Dec; 66(12):2797-800. PubMed ID: 21933787
[TBL] [Abstract][Full Text] [Related]
12. Comparison of E-test and disc diffusion methods for the in vitro evaluation of the antimicrobial activity of colistin in multi-drug resistant Gram-negative Bacilli.
Somily AM
Saudi Med J; 2010 May; 31(5):507-11. PubMed ID: 20464039
[TBL] [Abstract][Full Text] [Related]
13. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of clinical isolates of gram-positive and gram-negative organisms to cefatrizine.
Carlone NA; Cuffini AM; Forno Pizzoglio M; Cavallo G
Drugs Exp Clin Res; 1985; 11(7):447-51. PubMed ID: 3836867
[TBL] [Abstract][Full Text] [Related]
15. New thioureides of 2-(4-methylphenoxymethyl) benzoic acid with antimicrobial activity.
Drăcea O; Larion C; Chifiriuc MC; Raut I; Limban C; Niţulescu GM; Bădiceanu CD; Israil AM
Roum Arch Microbiol Immunol; 2008; 67(3-4):92-7. PubMed ID: 19496477
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
Giamarellou H
Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antibacterial activity of benzyl-[3-(benzylamino-methyl)-cyclohexylmethyl]-amine derivatives.
Kumar D; Joshi S; Rohilla RK; Roy N; Rawat DS
Bioorg Med Chem Lett; 2010 Feb; 20(3):893-5. PubMed ID: 20047831
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
Deshpande L; Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):73-5. PubMed ID: 15380281
[TBL] [Abstract][Full Text] [Related]
19. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now.
Freire-Moran L; Aronsson B; Manz C; Gyssens IC; So AD; Monnet DL; Cars O;
Drug Resist Updat; 2011 Apr; 14(2):118-24. PubMed ID: 21435939
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of susceptibility testing methods for polymyxin.
Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC
Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
